Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
SCRI Development Innovations, LLC
Medical University of South Carolina
HealthPartners Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, Davis
University of New Mexico
SCRI Development Innovations, LLC